Connect with us


Finerenone limits AFib in patients with chronic kidney disease, Type 2 diabetes – Cardiovascular Business



Article feature image

Treatment with finerenone can help limit new-onset atrial fibrillation (AFib) among patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D), according to new data presented at ACC.21, the American College of Cardiologys 70th annual scientific session.
In the FIDELIO-DKD trial, researchers had already concluded that finerenone, a mineralocorticoid receptor antagonist, reduces the risk of cardiovascular complications in patients with CKD and T2D. This secondary analysis of that same data…

Click here to view the original article.

Continue Reading

You might also like ...

Article feature image
Myths and stigma about ADHD contribute to poorer mental health for those affected – The Conversation AU
Article feature image
Researchers develop new therapeutic approach for treating acute myeloid leukemia – News-Medical.Net